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Background
Familial Mediterranean Fever (FMF) is characterized by
recurrent attacks of fever and serositis. Amyloidosis is its
most crucial complication. Methods: Between 2002 and
2007, 29 patients (11 girls, 18 boys) median age 316
months in whom FMF was diagnosed and with a follow-
up period of at least six months were included in the
study.
The mean age of the patients at the time of the onset was
110 +- 106 months. Genetic mutations more frequently
detected were M680I (12/29) and M694V (8/29). Age of
starting colchicine was 267 +- 180 months. The patients
were followed at 6 month intervals; at each visit, daily uri-
nary protein excretions were calculated.
Results
5 patients showed a proteinuric stage without fever
attacks, but two of them were non compliant with the
treatment.
There were no significant differences (age at onset, initial
dose of colchicine and serum amyloid A levels) in the two
groups. The FMF patients with elevated proteinuria
showed a short time between the age of onset and the
starting of colchicine than ones with normal proteinuria.
Two patients with pathological proteinuria did not have
MEFV gene mutations. After the increase of colchicine,
there was the complete resolution of proteinuria in all
patients.
Conclusion
Colchicine is an effective medication in the prevention
and treatment of amyloidosis; In contrast to other
reported studies, there was no correlation between amy-
loidosis and M694V homozygosity in this cohort. Ten
patients of our population who received a delayed diag-
nosis (median age of diagnosis 40 years) don't show renal
damage.
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